Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus
Abstract Background Interest in the study of type 1 diabetes mellitus (T1DM) and multiple sclerosis (MS) has increased because of their significant negative impact on the patient quality of life and the profound implications for the health care system. Although the clinical symptoms of T1DM differ f...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Molecular Medicine |
| Online Access: | https://doi.org/10.1186/s10020-025-01084-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862013138305024 |
|---|---|
| author | Fátima Cano-Cano Almudena Lara-Barea Álvaro Javier Cruz-Gómez Francisco Martín-Loro Laura Gómez-Jaramillo María Carmen González-Montelongo María Mar Roca-Rodríguez Lucía Beltrán-Camacho Lucía Forero Javier J. González-Rosa Mª Carmen Durán-Ruiz Ana I. Arroba Manuel Aguilar-Diosdado |
| author_facet | Fátima Cano-Cano Almudena Lara-Barea Álvaro Javier Cruz-Gómez Francisco Martín-Loro Laura Gómez-Jaramillo María Carmen González-Montelongo María Mar Roca-Rodríguez Lucía Beltrán-Camacho Lucía Forero Javier J. González-Rosa Mª Carmen Durán-Ruiz Ana I. Arroba Manuel Aguilar-Diosdado |
| author_sort | Fátima Cano-Cano |
| collection | DOAJ |
| description | Abstract Background Interest in the study of type 1 diabetes mellitus (T1DM) and multiple sclerosis (MS) has increased because of their significant negative impact on the patient quality of life and the profound implications for the health care system. Although the clinical symptoms of T1DM differ from those of MS, such as pancreatic β-cell failure in T1DM and demyelination in the central nervous system (CNS) in MS, both pathologies are considered as autoimmune-related diseases with shared pathogenic pathways, which include autophagy, inflammation and degeneration, among others. Considering the challenges in obtaining pancreatic β-cells and CNS tissue from patients with T1DM and MS, respectively, it is fundamental to explore alternative methods for evaluating disease status. Proteomic analysis of peripheral blood mononuclear cells (PBMCs) is an ideal approach for identifying novel and potential biomarkers for both autoimmune diseases. Methods We conducted a proteomic analysis of PBMCs from patients with T1DM and relapsing remitting Multiple Sclerosis (herein forth MS) patients (n = 9 per condition), using a label-free quantitative proteomics approach. The patients were diagnosed following the American Diabetes Association (ADA) criteria for T1DM and McDonald criteria for MS respectively, and were aged over 18 years and more than 2 years from the onset respectively. Results A total of 2476 proteins were differentially expressed in PBMCs from patients with T1DM and MS patients compared with those form healthy controls (H). Predictive analysis highlighted 15 common proteins, up- or downregulated in PBMCs from patients with T1DM and MS patients vs. healthy controls, involved in the immune system activity (BTF3, TTR, CD59, CSTB), diseases of the neuronal system (TTR), signal transduction (STMN1, LAMTOR5), metabolism of nucleotides (RPS21), proteins (TTR, ENAM, CD59, RPS21, SRP9) and RNA (SRSF10, RPS21). In addition, this study revealed both shared and distinct molecular patterns between the two conditions. Conclusions Compared with H, patients with T1DM and MS presented a specific expression pattern of common proteins has been identified. This pattern underscores the shared mechanisms involved in their immune responses and neurological complications, alongside dysregulation of the autophagy pathway. Notably, CSTB has emerged as a differential biomarker, distinguishing between these two autoimmune diseases. |
| format | Article |
| id | doaj-art-f002d68f7a8a457699e304263e87f942 |
| institution | Kabale University |
| issn | 1528-3658 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Medicine |
| spelling | doaj-art-f002d68f7a8a457699e304263e87f9422025-02-09T12:42:17ZengBMCMolecular Medicine1528-36582025-02-0131111710.1186/s10020-025-01084-xExploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitusFátima Cano-Cano0Almudena Lara-Barea1Álvaro Javier Cruz-Gómez2Francisco Martín-Loro3Laura Gómez-Jaramillo4María Carmen González-Montelongo5María Mar Roca-Rodríguez6Lucía Beltrán-Camacho7Lucía Forero8Javier J. González-Rosa9Mª Carmen Durán-Ruiz10Ana I. Arroba11Manuel Aguilar-Diosdado12Diabetes Mellitus Laboratory, Institute of Research and Biomedical Innovation of Cadiz (INiBICA)Diabetes Mellitus Laboratory, Institute of Research and Biomedical Innovation of Cadiz (INiBICA)Psychology Department, Institute of Research and Biomedical Innovation of Cadiz (INiBICA), University of CadizDiabetes Mellitus Laboratory, Institute of Research and Biomedical Innovation of Cadiz (INiBICA)Diabetes Mellitus Laboratory, Institute of Research and Biomedical Innovation of Cadiz (INiBICA)Diabetes Mellitus Laboratory, Institute of Research and Biomedical Innovation of Cadiz (INiBICA)Diabetes Mellitus Laboratory, Institute of Research and Biomedical Innovation of Cadiz (INiBICA)Biomedicine, Biotechnology and Public Health Department, Science Faculty, Biomedical Research and Innovation Institute of Cadiz (INIBICA), Cádiz UniversityNeurology Department, Spain. Institute of Research and Biomedical Innovation of Cadiz (INiBICA), Puerta del Mar University HospitalPsychology Department, Institute of Research and Biomedical Innovation of Cadiz (INiBICA), University of CadizBiomedicine, Biotechnology and Public Health Department, Science Faculty, Biomedical Research and Innovation Institute of Cadiz (INIBICA), Cádiz UniversityDiabetes Mellitus Laboratory, Institute of Research and Biomedical Innovation of Cadiz (INiBICA)Diabetes Mellitus Laboratory, Institute of Research and Biomedical Innovation of Cadiz (INiBICA)Abstract Background Interest in the study of type 1 diabetes mellitus (T1DM) and multiple sclerosis (MS) has increased because of their significant negative impact on the patient quality of life and the profound implications for the health care system. Although the clinical symptoms of T1DM differ from those of MS, such as pancreatic β-cell failure in T1DM and demyelination in the central nervous system (CNS) in MS, both pathologies are considered as autoimmune-related diseases with shared pathogenic pathways, which include autophagy, inflammation and degeneration, among others. Considering the challenges in obtaining pancreatic β-cells and CNS tissue from patients with T1DM and MS, respectively, it is fundamental to explore alternative methods for evaluating disease status. Proteomic analysis of peripheral blood mononuclear cells (PBMCs) is an ideal approach for identifying novel and potential biomarkers for both autoimmune diseases. Methods We conducted a proteomic analysis of PBMCs from patients with T1DM and relapsing remitting Multiple Sclerosis (herein forth MS) patients (n = 9 per condition), using a label-free quantitative proteomics approach. The patients were diagnosed following the American Diabetes Association (ADA) criteria for T1DM and McDonald criteria for MS respectively, and were aged over 18 years and more than 2 years from the onset respectively. Results A total of 2476 proteins were differentially expressed in PBMCs from patients with T1DM and MS patients compared with those form healthy controls (H). Predictive analysis highlighted 15 common proteins, up- or downregulated in PBMCs from patients with T1DM and MS patients vs. healthy controls, involved in the immune system activity (BTF3, TTR, CD59, CSTB), diseases of the neuronal system (TTR), signal transduction (STMN1, LAMTOR5), metabolism of nucleotides (RPS21), proteins (TTR, ENAM, CD59, RPS21, SRP9) and RNA (SRSF10, RPS21). In addition, this study revealed both shared and distinct molecular patterns between the two conditions. Conclusions Compared with H, patients with T1DM and MS presented a specific expression pattern of common proteins has been identified. This pattern underscores the shared mechanisms involved in their immune responses and neurological complications, alongside dysregulation of the autophagy pathway. Notably, CSTB has emerged as a differential biomarker, distinguishing between these two autoimmune diseases.https://doi.org/10.1186/s10020-025-01084-x |
| spellingShingle | Fátima Cano-Cano Almudena Lara-Barea Álvaro Javier Cruz-Gómez Francisco Martín-Loro Laura Gómez-Jaramillo María Carmen González-Montelongo María Mar Roca-Rodríguez Lucía Beltrán-Camacho Lucía Forero Javier J. González-Rosa Mª Carmen Durán-Ruiz Ana I. Arroba Manuel Aguilar-Diosdado Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus Molecular Medicine |
| title | Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus |
| title_full | Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus |
| title_fullStr | Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus |
| title_full_unstemmed | Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus |
| title_short | Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus |
| title_sort | exploring proteomic immunoprofiles common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus |
| url | https://doi.org/10.1186/s10020-025-01084-x |
| work_keys_str_mv | AT fatimacanocano exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus AT almudenalarabarea exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus AT alvarojaviercruzgomez exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus AT franciscomartinloro exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus AT lauragomezjaramillo exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus AT mariacarmengonzalezmontelongo exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus AT mariamarrocarodriguez exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus AT luciabeltrancamacho exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus AT luciaforero exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus AT javierjgonzalezrosa exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus AT macarmenduranruiz exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus AT anaiarroba exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus AT manuelaguilardiosdado exploringproteomicimmunoprofilescommonneurologicalandimmunologicalpathwaysinmultiplesclerosisandtype1diabetesmellitus |